Supplementary Figures of Key Therapeutic Agents for Thymic Carcinoma in Real-world Clinical Practice
figure
posted on 2024-11-16, 02:45 authored by Akiko TateishiAkiko Tateishi, Yusuke Okuma, Yasushi Goto, Yukiko Igawa, Masahiro Torasawa, Yuki Shinno, Tatsuya Yoshida, Hidehito Horinouchi, Noboru Yamamoto, Yuichiro OheSupplementary Figure 1: Progression-free survival and overall survival for each treatment line.
Supplementary Figure 2: Progression-free survival for lenvatinib as the first-, or second or later-line treatment.
